Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Radiolabeled oligonucleotides for antisense imaging.

Iyer AK, He J.

Curr Org Synth. 2011 Aug 1;8(4):604-614.

2.

Antisense imaging: and miles to go before we sleep?

Lewis MR, Jia F.

J Cell Biochem. 2003 Oct 15;90(3):464-72. Review.

PMID:
14523980
3.
4.

99mTc-Hydrazinonicotinamide/tricine-eighteen-nucleotide RIα mRNA antisense small interfering oligoribonucleotides .

Cheng KT.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2007 Sep 21 [updated 2007 Oct 23].

5.

99mTc-N,N'-Bis(S-benzoyl-thioglycoloyl)diamidopropanoyl-KRAS-PNA-d(Cys-Ser-Lys-Cys).

Cheng KT, Chakrabarti A, Aruva MR, Thakur ML, Wickstrom E.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2007 Aug 9 [updated 2008 Jan 3].

6.

Radiolabelled oligonucleotides for imaging of gene expression with PET.

Lendvai G, Estrada S, Bergström M.

Curr Med Chem. 2009;16(33):4445-61. Review.

PMID:
19835563
7.

64Cu-N,N'-Bis(S-benzoyl-thioglycoloyl)diaminopropanoate-KRAS-PNA-d(Cys-Ser-Lys-Cys).

Cheng KT, Chakrabart A, Aruva MR, Thakur ML, Wickstrom E.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2007 Aug 10 [updated 2008 Jan 3].

8.

Early detection of chemoresistance in vivo through the use of a radiolabeled antisense oligonucleotide.

Touboul M, Gauchez AS, D'Hardemare Adu M, Lunardi J, Deverre JR, Pernin C, Mathieu JP, Vuillez JP, Fagret D.

Anticancer Res. 2002 Nov-Dec;22(6A):3349-56.

PMID:
12530086
9.
10.

[Prerequisites for diagnostic use of antisense oligonucleotides in nuclear medicine].

Hildebrandt M, Reske SN.

Nuklearmedizin. 1996 Aug;35(4):126-31. Review. German.

PMID:
9005406
11.

Antisense radiotherapy: targeting full-size mdrl mRNA with 125I-labelled oligonucleotides.

Gaidamakova EK, Neumann RD, Panyutin IG.

Int J Radiat Biol. 2004 Nov-Dec;80(11-12):889-93.

PMID:
15764398
12.
13.

Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.

White PJ, Anastasopoulos F, Pouton CW, Boyd BJ.

Expert Rev Mol Med. 2009 Mar 23;11:e10. doi: 10.1017/S1462399409001021. Review.

PMID:
19302730
14.

Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.

Oberbauer R.

Wien Klin Wochenschr. 1997 Jan 31;109(2):40-6. Review.

PMID:
9123943
15.

99mTc-CCND1-PNA-IGF1 Chimeras.

Cheng KT, Wickstrom E, Tian X, Aruva MR, Qin W, Zhu W, Duffy KT, Sauter ER, Thakur ML.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2006 Nov 1 [updated 2008 Jan 16].

16.
17.

A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.

Hussain M, Shchepinov M, Sohail M, Benter IF, Hollins AJ, Southern EM, Akhtar S.

J Control Release. 2004 Sep 14;99(1):139-55.

PMID:
15342187
18.

Potential use of radiolabeled antisense oligonucleotides in oncology.

Gauchez AS, Du Moulinet D'Hardemare A, Lunardi J, Vuillez JP, Fagret D.

Anticancer Res. 1999 Nov-Dec;19(6B):4989-97. Review.

PMID:
10697501
19.

Antisense oligonucleotides for cancer therapy-an overview.

Stahel RA, Zangemeister-Wittke U.

Lung Cancer. 2003 Aug;41 Suppl 1:S81-8. Review.

PMID:
12867066
20.

Antisense oligonucleotides as therapeutics for malignant diseases.

Ho PT, Parkinson DR.

Semin Oncol. 1997 Apr;24(2):187-202. Review.

PMID:
9129689
Items per page

Supplemental Content

Support Center